Oral cancer treatment: developments in chemotherapy and beyond.
about
Oral antineoplastic agents: how do we care about adherence?Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.Mobile Application to Promote Adherence to Oral Chemotherapy and Symptom Management: A Protocol for Design and DevelopmentReporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review.Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapyImpact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts.Acceptance of oral chemotherapy in breast cancer patients - a survey study.Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerationsThe development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stabilityAdvanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics.Safe practice and nursing care of patients receiving oral anti-cancer medicines: a position statement from UKONS.Oral chemotherapy safety practices at US cancer centres: questionnaire survey.Therapeutic applications of hydrogels in oral drug delivery.Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.Satraplatin: an orally available platinum analog for the treatment of cancer.Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer AgentsAdherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice.A Systematic Review of Adherence to Oral Antineoplastic TherapiesDo people with cancer comply with oral chemotherapy treatments?Development of imiquimod-loaded mucoadhesive films for oral dysplasia.Overcoming obstacles in accessing unfunded oral chemotherapy: physician experience and challenges.Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia.The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Adherence to oral antineoplastic agents by cancer patients: definition and literature review.Advances in oral delivery of anti-cancer prodrugs.MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4.Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles.Polymeric drug delivery systems for intraoral site-specific chemoprevention of oral cancer.pH-and thermo-sensitive pluronic/poly(acrylic acid) in situ hydrogels for sustained release of an anticancer drug.Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study.Effects of S-1 as a second-line chemotherapy for patients with relapsed pancreatic cancer.Towards safety of oral anti-cancer agents, the need to educate our pharmacistsxCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells.Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians.Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada.Patients' perspectives and safe handling of oral anticancer drugs at an Asian cancer center.Acacia catechu Ethanolic Seed Extract Triggers Apoptosis of SCC-25 Cells.The oral education clinic: A pharmacist- and nurse-led clinic to support patients starting oral systemic anti-cancer treatments.
P2860
Q28082909-6F6F37D8-4F5A-4363-B168-51D0F9F0F636Q33408664-44571D1B-29C1-4D2A-929C-FF7F13AE009AQ33454095-AF0114C3-5F29-4C86-9BF4-702069B9D4A8Q33455278-DBAD4F79-3575-4955-A097-D2089A9C899EQ33831232-42E30815-0442-4312-909E-B36A212809D0Q33847820-71A396F3-354D-4E9B-A1A9-257C9A510E95Q33870472-00F895A5-A2BC-4980-A9D2-F4FBE2B7AA1AQ34418437-1F7E2E29-708E-4D41-BA22-004D0EF2EB2CQ34570055-4CBB93C4-0AA4-439A-B1B6-832287ACAED1Q35376573-C5DC2546-5ED5-4411-A594-8D43E469FEBCQ35602151-E7C4D9D9-2C08-4952-BFD8-3BA7748E97BEQ35648821-ABDE1CE2-B2CE-4161-9237-59F75556820DQ35995914-C75F256A-5819-4147-B9BB-31B2929F73DDQ36271954-8AEB4F46-6B69-4B13-8F1C-790A4D3871FCQ36532071-6D1DF2E2-5376-4546-AEC6-E2D4B0CD9623Q36641981-64519515-071E-4D7B-93E7-65844EE9F93DQ36650721-3C33E014-5AAB-4A94-913C-7B617FE632BFQ36673490-4AD0B17B-38A0-4034-A0E1-168B7865958CQ36684867-B9899C87-69FB-4359-B6AD-A0E180F51D53Q36914702-CAA772F3-AAF9-416A-804D-2E0FA52D3EEDQ37008510-16DEE0C1-9C28-411B-9509-C614BEDBCFF8Q37334707-A18BFB86-7F20-4910-B699-5E58C560AF3CQ37617635-18C54C72-6373-4081-82F3-F473C51532B0Q38042003-EF20BAD5-8048-4B32-BEEA-E6F86993C398Q38082728-50B6B138-5D3C-438E-9794-AA4526ABD410Q38147533-6E7775AC-4C5F-4F80-AD7C-CE9A8AEB3BE8Q38862820-0A9DEEEF-326A-4C82-8051-3EEE7ABF83A9Q39017248-F1F83174-ADDB-41C7-B2DE-13E2B01964DDQ39041183-7360F57D-6EEE-4AB2-8896-266848F70617Q39398234-EB763E72-6223-473C-9E1E-081C2E9E760FQ39547558-FA7624CE-8270-415E-BF21-86CA021A5A80Q41966885-CD865408-93CE-4925-BBB5-AD3A037A87EAQ42013433-BACE5546-FF9A-453C-960E-8CEBBED74D65Q42222445-97FA864D-8B36-471D-BB3C-1B551852E744Q42722024-779E9504-6E41-439A-AC26-4A37319194F4Q44022495-AE4B6413-C364-4EB7-BE75-29B0FDA94ACCQ44802035-1F9E6C59-FA60-4F83-BAD0-33F9B21A25EAQ46145766-B1AFFB48-3031-46BC-8B74-634BB41B0D9BQ47116542-7F503640-CDD5-4627-8A08-12C2B7F5B97AQ47288134-B4554687-A42E-4AED-B0FA-D4CBC2B88CE0
P2860
Oral cancer treatment: developments in chemotherapy and beyond.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Oral cancer treatment: developments in chemotherapy and beyond.
@ast
Oral cancer treatment: developments in chemotherapy and beyond.
@en
Oral cancer treatment: developments in chemotherapy and beyond.
@nl
type
label
Oral cancer treatment: developments in chemotherapy and beyond.
@ast
Oral cancer treatment: developments in chemotherapy and beyond.
@en
Oral cancer treatment: developments in chemotherapy and beyond.
@nl
prefLabel
Oral cancer treatment: developments in chemotherapy and beyond.
@ast
Oral cancer treatment: developments in chemotherapy and beyond.
@en
Oral cancer treatment: developments in chemotherapy and beyond.
@nl
P2860
P356
P1476
Oral cancer treatment: developments in chemotherapy and beyond.
@en
P2093
C J Twelves
V J O'Neill
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600591
P407
P577
2002-10-01T00:00:00Z
2002-10-21T00:00:00Z
P5875
P6179
1043340140